Webinar Archive: 11 Market Access Questions to Address Prior to Launching Your First Specialty Drug

Getting answers to the eleven key questions covered in this webinar will help guide commercial teams in effectively launching specialty products.
Learning Objectives Covered in the Webinar:
-
- Identify the types of third-party organizations that can help support your specialty drug launch
- Understand the key considerations and composition of establishing third-party partnerships
- Determine the difference between having greater access or greater control, and how that can impact the commercial success of your launch
Market access considerations can be complex to navigate and overwhelming to address for biopharmaceutical commercial teams launching their first specialty drug. That’s where Archbow’s team of market access experts can help. Contact us today to get started.
For additional insights on this topic, you may also enjoy the following blog posts:
Archbow Consulting helps pharmaceutical and biotech companies in the USA and Europe design, build, and optimize product distribution and patient access strategies. Archbow was founded by industry veterans to meet a need in the marketplace for consulting options that offer diverse real-world experience, are able to leverage deep connections across the industry, and can also provide actionable strategic guidance. We invite you to learn more about our team, services, and clients’ success, and connect with us via email, LinkedIn or subscribing to this blog which you can do below.
Share in
Recent Posts
From Roadblocks to Runways: Aligning Services for a Smooth Patient Journey
Proven strategies for mapping and optimizing the patient journey, from diagnosis to ongoing care.
The Rise of Digital Health and Technology Integration in the Pharmaceutical Industry
In 2025, digital health is no longer a future consideration—it is a present imperative for key industry players in the pharmaceutical services sector, including manufacturers, specialty pharmacies, payers, and providers
Direct-to-Consumer (DTC) Changes Under the New Executive Order: What You Need to Know
As the US administration urges leading pharmaceutical manufacturers to implement MFN prescription drug pricing solutions, innovative approaches like DTC distribution for prescription medications are gaining increased attention.
SUBSCRIBE
Subscribe to receive news and updates from Archbow Consulting
|